A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

Phase 0 Recruiting 22 enrolled Grit Biotechnology Shanghai Changzheng Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy, and cellular metabolism kinetics of GT801 in the treatment of moderate-to-severe refractory autoimmune diseases. Interim analysis will be conducted when 5 patients complete primary endpoint measurement.

Timeline

Start: 2025-11-07
Primary completion: 2028-03-31
Completion: 2028-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GT801	Unknown	—	—

Indications

No indication recorded.